NEW YORK, may 19. /TASS/. American biotech company Moderna reported the successful clinical trials of a vaccine against the new coronavirus. A statement published Monday on the website of the company.
According to statistics, the clinical trial participants were divided into several groups and received different doses of the vaccine. Those who received the lowest dose of the vaccine, antibodies develop in about the same amount that is observed in people who recover from COVID-19 (coronavirus caused by the disease).
the vaccine Trials began on 16 March at the research center in Seattle (Washington state). They were conducted jointly by Moderna and specialists from the National institutes of health. The test was attended by 45 people.
“the Moderna Team at an accelerated pace works to start in July for the third phase of testing of the vaccine in case of success apply for licensing of the drug,” said CEO Stefan Bansal.
In early may, the US President Donald trump said that experts are likely to create a vaccine against coronavirus to the end of the year. Earlier, the Director of the National Institute of allergic and infectious diseases of the United States Anthony Fauci said that the us administration expects to develop by January 2021. Fauci stressed that the us government can’t guarantee this.
in Addition to the Moderna test of the vaccine in the United States are the company Inovio Pharmaceuticals and Pfizer, collaborating with the German company Biontech. A major manufacturer of pharmaceutical products Johnson & Johnson plans to begin testing its vaccine in September.
According to the Johns Hopkins University, which conducts calculations on the basis of information Federal and local authorities in the US were more than 1.48 million cases of infection with coronavirus. Died 89.5 thousand people.
